The standard of care (SoC) for medically operable patients with early-stage (stages I–IIIB)
NSCLC is surgery combined with (neo) adjuvant systemic therapy for patients with stages II …

Summary We analyzed 2,532 lung adenocarcinomas (LUAD) to identify the
clinicopathological and genomic features associated with metastasis, metastatic burden …

Objective: Overall survival is the gold-standard outcome measure for phase 3 trials, but the
need for a long follow-up period can delay the translation of potentially effective treatment to …

Introduction Increased efforts to optimize outcomes for early stage NSCLC through the
investigation of novel perioperative treatment strategies are ongoing. An emerging question …

Background Surrogate endpoints for overall survival in patients with resectable non–small
cell lung cancer receiving neoadjuvant therapy are needed to provide earlier treatment …

OBJECTIVES To evaluate the postoperative complications and 30-day mortality rates
associated with neoadjuvant chemotherapy before major anatomic lung resections …

Introduction Perioperative (neoadjuvant and adjuvant) pembrolizumab has shown favorable
efficacy in patients with early-stage non-small cell lung cancer (NSCLC). This study aims to …

The treatment paradigm for patients with stage II/III non-small-cell lung cancer (NSCLC) is
rapidly evolving. We performed a modified Delphi process culminating at the Early-stage …

Hepatocellular carcinoma remains a lethal malignancy and is an increasingly common
cause of cancer death worldwide. Curative-intent surgical resection remains the standard of …

Surgery is the standard of care for patients with operable non-small cell lung cancer
(NSCLC). However, as a single modality, surgery for early stage or locally advanced NSCLC …